EYPT Q4 2017 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$933,000-84.4% YoY

Gross Profit

-$3M-357.6% margin

Operating Income

-$6M-622.5% margin

Net Income

-$6M-619.7% margin

EPS (Diluted)

$-1.30

QoQ Revenue Growth

+142.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$606,000

Balance Sheet

Total Assets

$14M

Total Liabilities

$4M

Stockholders' Equity

$10M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$933,000	$6M	-84.4%
Gross Profit	-$3M	$3M	-218.9%
Operating Income	-$6M	-$94,000	-6078.7%
Net Income	-$6M	-$67,000	-8529.9%